Elevated lipoprotein(a), often written as Lp(a), is an independent, genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD). Levels above 50 mg/dL are estimated to affect around 20 to 30 percent of the global population.
Although treatment options remain limited, clinical interest in Lp(a) has grown in recent years due to its strong prognostic value and the development of emerging targeted therapies. As Lp(a) testing becomes more widely recommended in guidelines, there is still uncertainty about how clinicians should respond to elevated results, particularly when there are no other clear treatment indications.
What New Research Shows
A new study presented at the American College of Cardiology examined how elevated Lp(a) levels influence clinical decision-making in routine practice.
Researchers found that higher Lp(a) levels were associated with slightly earlier and more frequent use of preventive cardiovascular medications. However, overall treatment changes were modest, particularly in a low-risk primary prevention population.
Limited Treatment Response in Low-Risk Patients
The study showed that nearly 80 percent of patients with elevated Lp(a) above 50 mg/dL did not begin lipid-lowering therapy if they did not have additional cardiovascular risk factors.
Use of more intensive treatments, such as PCSK9 inhibitors, was rare. Aspirin initiation was also uncommon, although both were slightly more frequent in patients with elevated Lp(a).
Overall, the findings suggest that elevated Lp(a) only occasionally influences prescribing decisions, and responses tend to be selective rather than consistent.
Lp(a) as a Risk Marker, Not a Direct Treatment Target
According to corresponding author Sheilah A. Bernard of Boston University Chobanian & Avedisian School of Medicine, elevated Lp(a) is increasingly used as a “risk enhancer” rather than a standalone treatment target.
While it is not currently an indication for statin therapy on its own, clinicians may use it to guide more aggressive preventive strategies in selected patients.
However, no therapies are currently approved specifically for lowering Lp(a), and current guidelines focus on its role in refining overall cardiovascular risk assessment rather than directing treatment alone.
Study Design and Findings
The researchers conducted a multicentre retrospective observational study involving nearly 15,000 low-risk patients undergoing Lp(a) testing.
Key findings within 90 days of testing included:
-
Lipid-lowering therapy was more likely in patients with elevated Lp(a), but still uncommon overall
-
PCSK9 inhibitor use was rare, even among those with high Lp(a)
-
Aspirin initiation was also uncommon, though slightly higher in the elevated Lp(a) group
Importantly, the authors emphasised that these prescribing patterns reflect real-world clinical behaviour rather than guideline-based recommendations.
Key Takeaways
-
Lp(a) is a genetically determined risk factor for cardiovascular disease
-
Elevated levels are relatively common, affecting up to 30 percent of people
-
There are currently no approved treatments specifically targeting Lp(a)
-
Clinicians may use Lp(a) as a risk enhancer rather than a treatment trigger
-
Real-world prescribing changes after testing are still limited
Publication
The findings were published in the American Journal of Preventive Cardiology.
